Synamics Therapeutics Attracts Former Executives from Novozymes as Lead Investors for AI-Driven Drug Discovery
Wednesday, July 17, 2024
Synamics Therapeutics, a startup focused on using AI for drug discovery to combat drug resistance in cancer, has received significant backing in its pre-seed funding round from two prominent figures in biotechnology. Steen Riisgaard and Per Falholt, well-known in the industry for their roles at Novozymes and other biotech ventures, are leading the investment.
The company aims to develop novel therapies to address drug resistance in cancer, a critical challenge in oncology today. The funding will support the validation of its Dynaptive™ drug design platform.
"We are pleased to welcome Steen Riisgaard and Per Falholt as lead investors," said Violet Zahedi, CEO of Synamics Therapeutics. "Their support not only validates our approach but also accelerates our mission to revolutionize cancer treatment with AI. Their expertise will be invaluable as we innovate and push the boundaries of drug discovery."
Steen Riisgaard, known for his leadership at Novozymes, commented, "Investing in Synamics Therapeutics aligns with my commitment to advancing healthcare solutions. Their approach to drug discovery has potential for significant patient impact, and I'm eager to contribute to their journey."
Per Falholt, who has a strong background in launching biotech products, added, "I'm excited to support Synamics in addressing drug-resistant cancers. Their AI-driven platform shows great promise, and I look forward to helping them tackle this pressing challenge in oncology."
Synamics Therapeutics aims to make significant progress in combating drug-resistant cancers, ensuring better outcomes for patients through continuous innovation and staying ahead of cancer's adaptive capabilities.
Source: prnewswire.com
